Division of Merck & Co. Inc.
Latest From Viralytics Ltd.
The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.
A late-phase assessment of the oncolytic virus in liver cancer patients was stopped early for futility but Transgene thinks the failure is an isolated event.
AstraZeneca inks a deal with French firm Transgene to co-develop five armed oncolytic vaccinia virus candidates in an area that is hotting up for big pharma.
Recently battered by clinical setbacks, Immune Design has a co-development partnership with Merck around Keytruda and Merck’s Perlmutter is a former board member. Merck would pay roughly $300m to acquire the company and its immune system-boosting technologies.
- Therapeutic Areas
- Parent & Subsidiaries
- Merck & Co. Inc.
- Senior Management
Malcolm McColl, Managing Dir. & CEO
Robert Vickery, CFO
Darren Shafren, PhD, CSO
- Contact Info
Phone: 2 9988 4000
Ste. 305, Level 3
66 Hunter St.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.